申请人:Sterling Drug Inc.
公开号:US04299830A1
公开(公告)日:1981-11-10
4-Q-9-RR'N-3,4,5,6-tetrahydro-2H-1,5-methano-1,4-benzodiazocines wherein Q is propyl, isobutyl, neopentyl, allyl, 2-methyl-2-propenyl, 2-chloro-2-propenyl, cis-3-chloro-2-propenyl, cis-3-chloro-2-butenyl, trans-3-chloro-2-butenyl, propargyl, cyclopropylmethyl or (2,2-dichlorocyclopropyl)methyl; and R and R' are both hydrogens or both methyls; or R is hydrogen and R' is methyl, ethyl, propyl, butyl, isobutyl or benzyl and acid addition salts thereof are useful as strong analgesics and are prepared from the known 3,4,5,6-tetrahydro-2H-1,5-methano-1,4-benzodiazocine by multi-step processes including acylation (including acetylation), nitration, nitro reduction, amide reduction, deacetylation, alkylation and dimethylation.
4-Q-9-RR'N-3,4,5,6-四氢-2H-1,5-甲基-1,4-苯并二氮杂环中,其中Q为丙基、异丁基、新戊基、烯丙基、2-甲基-2-丙烯基、2-氯-2-丙烯基、顺-3-氯-2-丙烯基、顺-3-氯-2-丁烯基、反-3-氯-2-丁烯基、丙炔基、环丙甲基或(2,2-二氯环丙基)甲基;R和R'均为氢或甲基;或R为氢,而R'为甲基、乙基、丙基、丁基、异丁基或苄基。这些化合物的酸盐加成物可用作强烈止痛药,并通过多步反应制备自已知的3,4,5,6-四氢-2H-1,5-甲基-1,4-苯并二氮杂环,包括酰化(包括乙酰化)、硝化、硝基还原、酰胺还原、脱乙酰、烷基化和二甲基化。